Chemoradiation paradigm for the treatment of lung cancer

Nature Clinical Practice Oncology

Volumn 3, Issue 4, 2006, Pages 188-199

  Eberhardt, Wilfried ^a   Pöttgen, Christoph ^a   Stuschke, Martin ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Chemoradiation; Chemotherapy; Cisplatin; Non small cell lung cancer; Stage III

Indexed keywords

AMIFOSTINE; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; LOMUSTINE; MITOMYCIN; NAVELBINE; PACLITAXEL; PLACEBO; VINBLASTINE; VINDESINE;

ANGIOGENESIS; AREA UNDER THE CURVE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG TARGETING; ESOPHAGITIS; HUMAN; INFECTION; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAINTENANCE THERAPY; MEDLINE; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CLINICAL TRIALS, PHASE III; COMBINED MODALITY THERAPY; ETOPOSIDE; HUMANS; LUNG NEOPLASMS; MULTICENTER STUDIES; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS;

EID: 33645726878     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0461     Document Type: Review

References (62)

1. Jemal A et al. (2005) Cancer Statistics, 2005. CA Cancer J Clin 55: 10-30
2. Travis WD et al. (2004) Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC.
3. Mountain CF (1997) Revisions in the International System for Staging Lung Cancer. Chest 111: 1711-1717
4. Ginsberg RJ et al. (2001) Non-small-cell lung cancer. In Cancer: Principles and Practice of Oncology, edn 6, 925-983 (Eds DeVita VT Jr et al.) Philadelphia: Lippincott
5. Eberhardt W et al. (2003) Induction therapy before surgery in stage III non-small-cell lung cancer: IASLC Brugges Consensus. Lung Cancer 42 (Suppl 1): S9-S14
6. Farray D et al. (2005) Multimodality therapy for stage III non-small-cell lung cancer. J Clin Oncol 23: 3257-3269
7. Perez CA et al. (1987) Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Cancer 59: 1874-1881
8. Albain KS et al. (1995) Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: Mature results of Southwest Oncology Group Phase II Study 8805. J Clin Oncol 13: 1880-1892
9. Eberhardt W et al. (1998) Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: Mature results of a phase-II trial. J Clin Oncol 16: 622-634
10. Eberhardt WE et al. (2005) The role of surgery in stage IIIA non-small cell lung cancer. Hematol Oncol Clin North Am 19: 303-319
11. Stuschke M et al. (1999) Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: long-term follow-up and investigations of late neuro-psychologic effects. J Clin Oncol 17: 2700-2709
12. Dewey WC and Bedford JS (2004) Radiobiologic principles. In Textbook of Radiation Oncology, edn 2, 3-29 (Eds Leibel SA and Phillips TL) Philadelphia: Saunders
13. Weichselbaum RR et al. (1995) Cellular and molecular mechanisms of radioresistance. Cancer Treat Res 74: 131-140
14. Dische S and Saunders MI (1990) The rationale for continuous, hyperfractionated, accelerated radiotherapy (CHART). Int J Radiat Oncol Biol Phys 19: 1317-1320
15. Withers HR et al. (1988) The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 27: 131-146
16. Milas L et al. (1995) Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res 55: 3564-3568
17. Chabner B (1993) The biological basis of cancer chemotherapy. Ann Intern Med 118: 633-637
18. Calabresi P and Chabner B (2001) Chemotherapy of neoplastic diseases. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, edn 10, 1381-1459 (Eds Gilman A et al.) New York: McGraw-Hill
19. Zamble DB et al. (1996) Repair of cisplatin-DNA by the mammalian excision nuclease. Biochemistry 35: 10004-10013
20. Milas L et al. (1999) Combination of taxanes with radiation: Preclinical studies. Semin Radiat Oncol 9: 12-26
21. Milas L et al. (2001) Docetaxel and radiation in lung cancer: preclinical investigations. Adv Lung Cancer 3: 6-8
22. Milas L et al. (1999) Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 59: 107-114
23. Edelstein et al. (1995) Potentiation of radiotherapy by Navelbine (NVB) in a human non-small cell lung cancer (NSCLC) line [abstract #611]. Proc Am Assoc Cancer Res 36
24. Niero A et al. (1999) Paclitaxel and radiotherapy: Sequence-dependent efficacy - a preclinical model. Clin Cancer Res 5: 2213-2222
25. Steel GG et al. (1979) Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity. Int J Radiat Oncol Biol Phys 5: 85-91
26. Tannock IF et al. (1996) Treatment of cancer with radiation and drugs. J Clin Oncol 52: 3156-3174
27. Herscher LL et al. (1999) Principles of chemoradiation: Theoretical and practical considerations. Oncology 13 (Suppl 5): S11-S22
28. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899-909
29. International Adjuvant Lung Cancer Trial Collaborative Group (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350: 351-360
30. Vokes EE et al. (1997) Combined modality therapy of solid tumours. Lancet 349 (Suppl 2): SII4-SII6
31. Dillman RO et al. (1996) Improved survival of stage III non-small cell lung cancer: Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 88: 1210-1215
32. Le Chevalier T et al. (1992) Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. J Natl Cancer Inst 84: 58
33. Arriagada R et al. (1997) Cisplatin-based chemoradiotherapy in patients with locally advanced non-small-cell lung cancer (NSCLC): Late analysis of a French randomized trial [abstract #446]. Proc Am Soc Clin Oncol 16
34. Sause WT et al. (2000) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, Southwest Oncology Group. Chest 117: 358-364
35. Brodin O et al. (1996) Comparison of induction chemotherapy before radiotherapy with radiotherapy only in patients with locally advanced squamous cell carcinoma of the lung. Eur J Cancer 32A: 1893-1900
36. Hotta K et al. (2004) Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 22: 3852-3859
37. Trovo M et al. (1992) Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 24: 11-15
38. Schaake-Koning C et al. (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326: 524-530
39. Cakir S and Egehan I (2004) A randomised clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III non-small cell lung cancer. Lung Cancer 43: 309-316
40. Blanke C et al. (1995) Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small cell lung cancer: A Hoosier Oncology Group Protocol. J Clin Oncol 13: 1425-1429
41. Clamon G et al. (1999) Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: A phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 17: 4-11
42. Groen H et al. (2004) Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: A multicenter phase III study. Ann Oncol 15: 427-432
43. Vokes EE et al. (2002) Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B study 9431. J Clin Oncol 20: 4191-4198
44. Furuse K et al. (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17: 2692-2699
45. Curran W et al. (2003) Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410 [abstract #621]. Proc Am Soc Clin Oncol 22
46. Fournel P et al. (2005) Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol [doi: 10.1200/JCO.2005.03.070]
47. Huber RM et al. (2003) Induction chemotherapy and following simultaneous radio/chemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (stage IIIA/IIIB) [abstract #622]. Proc Am Soc Clin Oncol 22
48. Vokes EE et al. (2004) Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): Initial analysis of a randomized phase III trial [abstract #7005]. J Clin Oncol 22 (Suppl)
49. Albain KS et al. (2005) Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309). J Clin Oncol 23: 624S
50. Ball D et al. (1999) A phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small-cell lung cancer: Final report of an Australian multi-centre trial. Radiother Oncol 52: 129-136
51. Belani C et al. (2005) Phase-III study of the Eastern Cooperative Oncology Group: Induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accellerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 23: 3760-3767
52. Schild SE et al. (2002) Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 54: 370-378
53. Movsas B et al. (2005) Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation Therapy Oncology Group trial 98-01. J Clin Oncol 23: 2145-2154
54. Gandara D et al. (2003) Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: Phase-II Southwest Oncology Group Study S9504. J Clin Oncol 21: 2004-2010
55. Kelly K et al. (2005) Low incidence of pneumonitis on SWOG 0023: A preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non-small cell lung cancer [abstract #7058]. J Clin Oncol 23
56. Belani C et al. (2005) Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: A randomized phase II locally advanced multi-modality protocol. J Clin Oncol [doi: 10.1200/JCO.2005.55.405]
57. Rowell NP et al. (2005) Concurrent chemoradiotherapy in non-small-cell lung cancer. The Cochrane Database of Systematic Reviews, Issue 4, Art No CD002140
58. Bonner JA et al. (2004) Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. 22: S5507
59. Kim DW et al. (2004) Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 59 (Suppl): S11-S20
60. Raben D et al. (2004) Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective. Int J Radiat Oncol Biol Phys 59 (Suppl): S27-S38
61. Bradley J et al. (2005) Toxicity and outcome results of RTOG 9311: A phase I-II dose escalation study using three-dimensional conformal radiation therapy in patients with inoperable non-small cell lung cancinoma. Int J Radiat Oncol Biol Phys 61: 318-328
62. Socinski et al. (2004) Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: A dose-escalation phased trial. J Clin Oncol 22: 4341-4350